Spotlight
Specialty
Partners
CME/CE
Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
EP: 1.Best Practices for Molecular Testing in Early-Stage Breast Cancer
EP: 2.How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer
EP: 3.Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial
EP: 4.How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer
EP: 5.HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches
EP: 6.Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer
Now Viewing
EP: 7.Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer
EP: 8.Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer
EP: 9.HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners
EP: 10.Other Treatment Modalities for HR+ Metastatic Breast Cancer
EP: 11.Evolution in the Field of HR+ Breast Cancer Management
Related Videos
Related Content
